Psoriatic arthritis patients who stay on 1 anti-TNFi drug fare better

04/26/2013 | Family Practice News

Patients with psoriatic arthritis who switched to a second anti-tumor necrosis factor inhibitor drug had lower drug-survival rates at three years compared with those who remained on their first medication, researchers in Norway found. Switchers also showed much poorer responses in factors such as Disease Activity Score-28 remission and American College of Rheumatology-50 response than non-switchers. The findings were published in the journal Annals of the Rheumatic Diseases.

View Full Article in:

Family Practice News

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
Learning Assessment Specialist at India's Leading K12 Education Enterprise
XSEED Education (India)
Gurgaon (New Delhi Area)
RFP Specialist, Contract Position
ASCD
Alexandria, VA
DIRECTOR OF LANGUAGE DEVELOPMENT
BOULDER VALLEY SCHOOL DISTRICT
Boulder, CO
Program Officer, Teacher Development
Knowles Science Teaching Foundation
Moorestown, NJ
DIRECTOR OF HEALTH AND CULTURE
BOULDER VALLEY SCHOOL DISTRICT
Boulder, CO